Beleodaq (Belinostat) Patent Expiration, LOE Window & CMS Spending

Beleodaq (Belinostat) by Aurobindo Pharma: FDA Orange Book core substance LOE 2026-08-10 (last listed 2027-10-27), 0 AB generics, $1.2M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAurobindo Pharma
FDA Application & PathwayN206256 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2026-08-10
Last Listed Patent or Exclusivity Date2027-10-27
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.2M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 16.1% 2-yr change)